May 25, 2021 / 04:30PM GMT
Operator
Ladies and gentlemen, welcome to the AB Science web conference. I will now hand over to Alain Moussy. Sir, please go ahead.
Alain Moussy - AB Science S.A. - Co-Founder, Chairman, President, CEO & Scientific Director
Good evening, and good afternoon for the ones who are from the United States. My name is Alain Moussy, I'm the CEO of AB Science. And I have the pleasure to run you through our web call on the latest safety results of masitinib in first-line metastatic castrate-resistant prostate cancer.
The -- with me, there were 3 people -- experts in oncology who will answer the question that you will have in the second half of this presentation. There is a Professor Stéphane Oudard, who is Professor of Oncology at Georges Pompidou Hospital in Paris. Professor Theo de Reijke, who's Professor at the Amsterdam University Medical Centers. And Professor Olivier Hermine, who is our President, Chair of the Scientific Community of AB Science and Professor of Hematology at Hospital Necker.
So prostate cancer is still an unmet medical need.
AB Science SA Corporate Call Transcript
May 25, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers